Apolipoprotein CIII (Apo CIII) (APOC3) Antibody – Goat Polyclonal

Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. [provided by RefSeq]

Function: Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles.

Subcellular location: Secreted.

Tissue specificity: Constitutes 50% of the protein fraction of VLDL and 2% of that of HDL. Synthesized predominantly in liver and to a lesser degree in intestine.

Post-translational modification: O-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan. Ref.9 Ref.10

Involvement in disease: Defects in APOC3 may be a cause of hyperalphalipoproteinemia (HYPALIP) [

MIM:143470]. Affected individuals show high levels of alpha-lipoprotein (high density lipoprotein/HDL). Ref.11

Sequence similarities: Belongs to the apolipoprotein C3 family.